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Education and debate
Need for differential discounting of costs and health
effects in cost effectiveness analyses
Werner B F Brouwer, Louis W Niessen, Maarten J Postma, Frans F H Rutten
The decision of the National Institute for Health and Clinical Excellence to abandon differential
discounting of future health is a step backwards and could change funding decisions
Discounting can have a strong influence on cost effec-
tiveness ratios for priority setting, especially in preven-
tive interventions. It is therefore crucial that appropri-
ate discount rates are used in economic evaluations.
Increasingly, it is argued that the rate for future
non-monetary health effects should be below that for
future costs, to account for the growing value of health
effects. The previous guidelines of the National
Institute for Health and Clinical Excellence (NICE) on
economic evaluation were the first national guidelines
to prescribe such differential discounting (6% for costs
and 1.5% for effects). However, in its latest guidelines
both rates are set at 3.5%, implying a lower weight for
future effects.1 We argue that this change is not based
on contemporary health economic literature nor con-
vincingly justified.
Discounting
Decisions about the resources dedicated to prevention
depend on the weight given to future health in
economic evaluations. Future costs and health gains
are commonly weighted in relation to the time at
which they occur, future costs and effects receiving less
weight than present ones. This procedure is called
discounting2 and is prescribed in international and
BMJ guidelines for economic evaluations of health
care.3–5
Although discounting may seem a rather technical
procedure, its consequences on the cost effectiveness
ratio are often substantial.2 4 6–8 Attaching lower weight
to future health makes preventive health care seem less
cost effective because such interventions typically
involve current costs and future effects (table). Thus,
the rate at which costs and effects are discounted can
affect funding decisions.
Problems with current practice
International and national guidelines and practical
studies agree that cost and effects should be
discounted, normally using an equal discount rate of
3-5%.8 Equal discounting is recommended irrespective
of how the effects are expressed—for example, in
money terms, as quality adjusted life years (QALYs), or
as life years gained. This consensus seems primarily
based on the consistency argument (box 1)13 and the
postponing paradox (box 2).14 Both arguments imply
that using different discount rates for costs and effects
would lead to undesirable decisions. If you agree with
these arguments, as most guidelines up till now
(implicitly) do, only one discount rate needs to be set
for both costs and effects. Normally, this rate is based
on monetary measures, such as the return on risk-free
government bonds.4
Both arguments underlying equal discounting have
been criticised.15–17 Firstly, it was argued that the money
value of health benefits such as QALYs is not stable but
may change over time, invalidating the consistency
argument.16 17 Secondly, the option of infinite postpon-
ing hardly seems relevant in the real world.4 8 Indeed,
Effect of equal and differential discounting of money and health on cost effectiveness of preventive interventions from selected studies
that reported sensitivity analysis on discount rates
Study Subject (outcome)
Equal discounting
at 6%
Differential
discounting*
Walker et al9 Public place defibrillators (£/QALY) 47 671 41 146
Trotter and Edmunds10 Meningococcal C vaccine (£/life year gained) 15 710 3 845
UKPDS11 Improved blood pressure control in type 2 diabetes (£/event-free year gained) 1 049 434†
Torgerson and Raftery2 Prevention of hip fracture with hormone replacement therapy (£/fracture prevented) 42 374 7 362†
Torgerson and Raftery2 Prevention of hip fracture with vitamin D and calcium (£/fracture prevented) 28 022 15 646
Gray et al12 Intensive blood glucose control on type 2 diabetes (£/event-free year gained) 1 166 563
QALY=quality adjusted life year, UKPDS=UK prospective diabetes study.
*6% for money and 1.5% for health.
†0% discounting for health gains; value for 1.5% discounting not reported.
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although until recently the National Institute for
Health and Clinical Excellence used differential
discount rates for costs (6%) and effects (1.5%), it never
recommended postponing all new programmes. We
therefore question the need for equal discounting and
believe new discount rules need to be found.
Alternative strategies
A first way of finding appropriate discount rates could
be to directly measure time preferences for health and
money—that is, the weight people attach to future
health gains or costs relative to present ones. But
although empirical evidence on time preferences for
money and health is available, the estimates differ sub-
stantially (partly because of differences in the
methods). Moreover, discount rates for health often
turn out higher than those for money, and the
observed rates for both are often implausibly high.6 As
such, it is questionable whether data on individual
preferences can be meaningfully used in societal deci-
sions, which also need to consider future generations
and paternalistic concern for sufficient preventive
measures. The economist Pigou noted that “There is
wide agreement that the State should protect the inter-
ests of the future in some degree against the effects of
our irrational discounting and of our preference for
ourselves over our descendants.”18 We may therefore
need other, more normative rationales for choosing
discount rates.
Recently, an alternative discount rule was devel-
oped. Van Hout suggests that the discount rates for
health and costs need not be equal but depend on dis-
tinct aspects of both quantities, such as the growth rates
of national income and healthy life expectancy.17
Gravelle and Smith,16 moreover, show that the
monetary value of health effects is expected to grow
over time. This growth needs to be accounted for in
economic evaluations. When health effects are valued
monetarily this can be done by using a growing value
for health. When non-monetary quantities are used,
such as QALYs (as proposed in the NICE guidelines),
the growth can be accounted for by lowering the
discount rate for effects relative to that of costs—that is,
differential discounting. Following this strategy, Grav-
elle and Smith calculate that non-monetary health
effects should typically be discounted some 2% to 5%
less than costs, which implies a maximum discount rate
for health of 1.5% if costs are discounted at 3.5%.
Adopting differential discounting will thus (rightfully)
give more weight to future health effects, especially
since discount rates for health are normally set equal to
those for costs.
These arguments are gaining greater acceptance,
and differential discounting seems likely to be adopted
in other national guidelines.19 So why has NICE
returned to equal discounting at 3.5%?
Treasuring future health
NICE explains its return to equal discounting and
higher discount rates for health by simply indicating
that the “Annual rate of 3.5%, for both costs and health
effects, is based on the recommendations of the UK
Treasury.”1 The Treasury’s Green Book,20 in which its
recommendations are laid down, indeed prescribes a
single 3.5% discount rate for evaluations. A closer look
at the Treasury’s guideline, however, shows that it is
based on the same framework Gravelle and Smith use
to derive a discount rate for costs.17
Unfortunately, the Treasury, while recognising
QALYs as outcome measures, neither refers to nor
uses their expansion of this framework to derive an
appropriate discount rate for non-monetary health
effects. The Treasury therefore does not account for
the fact that equal discounting is inappropriate when
measures such as QALYs are used for effects, unless
the growing value of health is otherwise accounted for.
But the growing value of health is not accounted for in
the institute’s guidelines. Although NICE judges the
cost-effectiveness of a programme in comparison to
some monetary standard or range,21 it does not explic-
itly adjust this range in relation to the timing of effects
nor use a growing (monetary) value for QALYs. In
addition, dealing with this issue implicitly in the
decision making process seems undesirable and
obscures this process.
Therefore, the institute’s decision to use equal
discounting at 3.5% for costs and non-monetary effects
is unexpected and risks undervaluing future health in
decision making. It is also unnecessary since differen-
tial discounting is not so much in contradiction with
the Treasury’s recommendation but rather its correct
application in the context of non-monetary health
effects. Gravelle and Smith show how to combine
appropriate discount rates with the Treasury’s own
theoretical framework.16
The Treasury indicates that the discount rate can be
varied to analyse its effect on outcomes, and indeed
NICE prescribes advanced, probabilistic sensitivity
Box 1: Consistency argument
The consistency argument can be easily explained by considering
programmes A and B below:
Programme A costs £30 000 this year and has an effect of 1 QALY this year.
Programme B costs £30 000 in year 40 and has an effect of 1 QALY in year
40.
If we assume the monetary valuation of health effects remains equal over
the years, as the consistency argument does, it is easy to see that these two
programmes should receive equal priority. If we want to discount future
costs and effects and want identical programmes like A and B to receive
equal priority, the discount rate of costs (r) should equal that of effects (i),
since only then does the cost effectiveness ratio of B ((£30 000/(1+r)40)/(1/
(1+i)40) = £30 000/1) equal that of A (£30 000/1).
Box 2: Postponing paradox
The postponing paradox is based on the simple fact that if one uses lower
discount rates for effects than for costs postponing any given programme
will improve its cost effectiveness ratio.
Consider programme A from box 1 with a cost effectiveness ratio of
£30 000 per QALY. Assuming a 5% discount rate for costs and a zero
discount rate for effects, postponing the programme by one year would
improve its cost effectiveness ratio to £30 000/(1.05)1 = £28 571 per QALY.
Further postponement would again improve the ratio, since the cost
component declines more rapidly than the effect component (which in our
example stays stable because of the zero discount rate). The paradox is
therefore that a lower discount rate for effects makes infinite postponement
theoretically optimal but it is practically undesirable.
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analysis. But this can never be an alternative for using
appropriate discount rates. A small consolation may be
that the Treasury prescribes a declining discount rate
of 3.5% for the first 30 years, 3.0% for the years 31 to
75, 2.5% from year 76 to 125, and 2.0% from year 126
to year 200. However, it takes 200 years before the pre-
vious discount rate for health effects of 1.5% is reached,
and most healthcare evaluations are likely to look at
much shorter time spans.
Back to the future
NICE’s new guideline on discounting is an unexpected
step back in time. Not only could it have a large influ-
ence on decision making, it may prevent other
countries from adopting differential discounting.
Remedial action is both urgent and straightforward.
The institute can simply follow the recommendation of
the Treasury20 and use the correction indicated by
Gravelle and Smith in discounting health effects,16 set-
ting the discount rate for health at 1.5% again. Such a
step would be in line with current theoretical insights,
would rightfully improve the cost effectiveness of
prevention, and ensures a healthier consideration of
the future.
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Malpractice in Mexico: arbitration not litigation
Carlos Tena-Tamayo, Julio Sotelo
Accusations of malpractice often end in the courts, damaging the doctor-patient relationship and
encouraging defensive practice. In Mexico, an alternative system based on arbitration and
conciliation has been effective
The growing number of lawsuits against doctors seems
to be related to poor personal communication, unreal-
istic expectations of performance, the high costs of
medical attention, and better informed and more criti-
cal patients.1 2 A lucrative industry has developed
around this phenomenon. In response, doctors buy
expensive insurance, which seriously affects their
medical practice, summarised in the concept of
“defensive medicine.”3 The practice of defensive medi-
cine includes ordering excessive diagnostic procedures
and consultations to minimise the risks of being sued.4
Consequently, the cost of medical care increases,
promoting resentment in patients, which in turn
favours lawsuits, creating a vicious circle.5
Fear of being sued drives some doctors to
additional detrimental actions, such as abandoning
risky specialties; refusing to treat seriously ill patients;
and using clinical records and informed consent forms
Summary points
New National Institute for Health and Clinical
Excellence guidelines change the discount rates
for costs and effects from 6% and 1.5%
respectively to 3.5% for both
This change gives a lower weight to future health
effects and may worsen the cost effectiveness
ratio, especially for preventive interventions
Differential discounting is more appropriate
when non-monetary outcomes like QALYs are
used
NICE should return to a 1.5% discount rate for
effects
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National
Commission for
Medical Arbitration,
Mitla [250, Mexico
City 03020, Mexico
Carlos Tena-
Tamayo
national
commissioner
continued over
BMJ 2005;331:448–51
448 BMJ VOLUME 331 20-27 AUGUST 2005 bmj.com
 on 24 October 2006 bmj.comDownloaded from 
